Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRO NASDAQ:AVDL NASDAQ:MTSR NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$50.51-2.5%$51.56$21.34▼$58.40$4.13B-0.151.14 million shs1.01 million shsAVDLAvadel Pharmaceuticals$11.25+1.6%$9.54$6.38▼$17.30$1.07B1.421.17 million shs779,902 shsMTSRMetsera$39.65-0.9%$31.62$12.30▼$47.40$4.20BN/A748,635 shs752,750 shsRNAAvidity Biosciences$33.21-2.1%$31.34$21.51▼$56.00$4.09B0.912.03 million shs916,676 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.12%-3.32%-4.09%+26.42%+86.47%AVDLAvadel Pharmaceuticals-1.42%+3.94%+16.04%+28.72%-31.88%MTSRMetsera+1.37%-8.55%+37.90%+88.81%+3,998,999,900.00%RNAAvidity Biosciences+1.16%+1.16%+16.36%+9.67%-26.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.796 of 5 stars3.51.00.04.73.50.80.0AVDLAvadel Pharmaceuticals2.0841 of 5 stars3.51.00.00.02.01.70.6MTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ARNAAvidity Biosciences2.4518 of 5 stars4.50.00.00.03.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5063.33% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.3362.96% UpsideMTSRMetsera 3.00Buy$55.0038.71% UpsideRNAAvidity Biosciences 3.06Buy$66.3599.80% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, MTSR, RNA, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.007/11/2025RNAAvidity BiosciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.007/10/2025RNAAvidity BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$55.006/27/2025RNAAvidity BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$96.006/24/2025RNAAvidity BiosciencesSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.006/20/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$65.006/17/2025RNAAvidity BiosciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.006/11/2025RNAAvidity BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$65.006/10/2025MTSRMetseraGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$56.00 ➝ $62.006/10/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $75.006/10/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$57.00 ➝ $59.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AAVDLAvadel Pharmaceuticals$169.12M6.44N/AN/A$0.77 per share14.61MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/ARNAAvidity Biosciences$10.90M367.20N/AN/A$11.94 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A187.50N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/ARNAAvidity Biosciences-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)Latest AVDL, MTSR, RNA, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02N/AN/AN/AN/AN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A8/8/2025Q2 2025RNAAvidity Biosciences-$0.93N/AN/AN/A$1.61 millionN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80AVDLAvadel PharmaceuticalsN/A2.732.33MTSRMetseraN/A6.556.55RNAAvidity BiosciencesN/A16.9116.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AAVDLAvadel Pharmaceuticals69.19%MTSRMetseraN/ARNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%AVDLAvadel Pharmaceuticals5.20%MTSRMetseraN/ARNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableMTSRMetsera81105.06 millionN/AN/ARNAAvidity Biosciences190120.52 million115.90 millionOptionableAVDL, MTSR, RNA, and AKRO HeadlinesRecent News About These CompaniesAvidity Biosciences stock rises after FDA grants Breakthrough Therapy statusJuly 24 at 4:00 PM | investing.comAvidity Biosciences shares climb after FDA grants Breakthrough Therapy designationJuly 24 at 4:00 PM | msn.comAvidity granted FDA Breakthrough status for DMD therapyJuly 24 at 4:00 PM | thepharmaletter.comTAvidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 SkippingJuly 23 at 9:00 AM | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by AnalystsJuly 21 at 5:19 AM | marketbeat.comNew York State Common Retirement Fund Purchases 87,468 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)July 20, 2025 | marketbeat.comAvidity Biosciences: Three Accelerated Approval Shots Feels ExcessiveJuly 14, 2025 | seekingalpha.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's WhyJuly 14, 2025 | marketbeat.comAvidity Biosciences price target raised to $70 from $60 at Evercore ISIJuly 12, 2025 | msn.comAlps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)July 12, 2025 | marketbeat.comAvidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)July 6, 2025 | marketbeat.comAvidity Biosciences, Inc. (RNA) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.com7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...June 27, 2025 | benzinga.comAvidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor FitzgeraldJune 27, 2025 | marketbeat.comAvidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal yearJune 26, 2025 | investing.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from AnalystsJune 26, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. BernsteinJune 24, 2025 | marketbeat.comAvidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advanceJune 24, 2025 | investing.comAvidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027June 20, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the Start3 Catalysts Driving Plug Power’s Turnaround CaseBy Jeffrey Neal Johnson | July 18, 2025View 3 Catalysts Driving Plug Power’s Turnaround CaseForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffRigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermBy Leo Miller | July 22, 2025View Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermAVDL, MTSR, RNA, and AKRO Company DescriptionsAkero Therapeutics NASDAQ:AKRO$50.51 -1.31 (-2.53%) Closing price 04:00 PM EasternExtended Trading$50.01 -0.50 (-0.99%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Avadel Pharmaceuticals NASDAQ:AVDL$11.25 +0.18 (+1.63%) Closing price 04:00 PM EasternExtended Trading$11.24 -0.01 (-0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Metsera NASDAQ:MTSR$39.65 -0.34 (-0.85%) As of 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Avidity Biosciences NASDAQ:RNA$33.21 -0.71 (-2.09%) Closing price 04:00 PM EasternExtended Trading$33.34 +0.13 (+0.38%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.